ReviewJournal of nanobiotechnology2025
Advances in biomedical applications of Se-based nanozymes.
Review in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Dual-Targeted Biomimetic MoSeAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- Tailoring Cobalt-Based Nanomaterials through Doping and Vacancy Engineering for Advanced Hydrogen Evolution Reaction (HER) and Oxygen Evolution Reaction (OER) Electrolysis.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Thermostability Engineering in Therapeutic Antioxidant Enzymes: From Molecular Fundamentals to Oxidative Stress Applications.International journal of molecular sciences · 2026Review
- Selenium‑based nanotherapeutics promote healing of infected diabetic wounds via photothermal‑driven macrophage immunometabolic reprogramming and the NRF2/HIF‑1α axis.Journal of nanobiotechnology · 2026Article
- Metal-Functionalized Nanozymes in Antibacterial Wound Management: Recent Advances and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Se-Fe Hydrogel with Switchable Hyperthermia for Osteosarcoma Therapy.International journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Selenium (Se) is an essential trace element for the human body, serving as a component of several natural enzymes and playing a crucial role in a variety of biological functions. However, the extraction of natural selenoenzymes presents significant challenges, including high cost and instability. To address this challenge, researchers have initiated investigations into the potential of combining Se with nanotechnology. This approach involves the development of Se-based nanomaterials, including monomeric Se, Se dioxide, and molybdenum selenide, with the objective of replacing natural selenoenzymes. The objective of this review is to present a comprehensive overview of the recent advancements in Se-based nanozymes and to elucidate their potential for biomedical applications. This review commences with an examination of the typical enzyme-mimicking activities (e.g., peroxidase-POD, glutathione peroxidase-GPx, superoxide dismutase-SOD, catalase-CAT) that have been achieved by Se-based nanomaterials. Secondly, we examined the regulatory mechanisms that govern the activities of Se-based nanozymes. Subsequently, a synthesis of their applications in various diseases facilitated a more comprehensive understanding of the function of Se-based nanozymes and their potential therapeutic effects. Finally, an outlook on the future development of Se-based nanozymes was presented, including their potential for clinical applications and technical challenges that need to be addressed. The synthesis of these research advances is intended to provide a clearer perspective and direction for the application of Se-based nanozymes in biomedicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.